A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

NCT06208878 · tracked via the Priya Life Science USA tracker

Sponsor

CRISPR Therapeutics AG

Phase

Observational

Started

2023-11-22

Last updated

2025-08-14

Condition(s) studied

Hematologic MalignancySolid Malignancy

Investigational drug(s) / intervention(s)

Non Interventional

Non Interventional: Safety and Efficacy Assessment

Study summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document. * Must have received CRISPR CAR T cellular therapy. Exclusion Criteria: * There are no specific exclusion criteria.

Primary outcome measure(s)

The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment. — 15 years
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.

Trial sites (22)

Facility	City	Region
City of Hope	Duarte	California
Cedars Sinai	Los Angeles	California
Stanford	Stanford	California
Yale New Haven Hospital	New Haven	Connecticut
Emory	Atlanta	Georgia
University of Chicago	Chicago	Illinois
University of Kansas	Westwood	Kansas
University of Minnesota	Minneapolis	Minnesota
Washington University Saint Louis	St Louis	Missouri
MSKCC	New York	New York
Montefiore Medical Center	The Bronx	New York
Oregon Health and Science University	Portland	Oregon
University of Pennsylvania	Philadelphia	Pennsylvania
UT Southwestern	Dallas	Texas
MD Anderson Cancer Center	Houston	Texas
Methodist Hospital-Sarah Cannon	San Antonio	Texas
University of Utah-Huntsman Cancer Institute	Salt Lake City	Utah
Royal Prince Alfred Hospital	Camperdown	New South Wales
Peter MacCallum Cancer Center	Melbourne	Victoria
Sir Charles Gairdner	Nedlands	Australia
Princess Margaret	Toronto	Ontario
University Hospital Hamburg-Eppendorf	Hamburg	Germany

More CRISPR Therapeutics AG trials in the USA

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting

A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension Recruiting

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease Recruiting

Other trials for the same condition

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Recruiting

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens) Enrolling by invitation

An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06208878 on ClinicalTrials.gov ↗ ← All trials in the USA